Phase 3 study of survodutide versus placebo in adults with overweight or obesity without type 2 diabetes

Phase 3, randomised, double-blind trial in obesity and Overweight comparing Survodutide with Placebo (2 arms). Primary endpoints: Percentage change in body weight from baseline to Week 76 and Achievement of body weight reduction at least 5% from baseline to Week 76. Started Jan 2024; status: completed.